Table 2.
Analysis of basic characteristics between healthy and IBD patients in 16S rRNA cohort
| 16S rRNA Cohort | Total (n = 57) | Healthy (n = 19) | IBD (n = 38) | P |
|---|---|---|---|---|
| Sex, n(%) | 1.000 | |||
| Female | 21 (36.84) | 7 (36.84) | 14 (36.84) | |
| Male | 36 (63.16) | 12 (63.16) | 24 (63.16) | |
| Age, M (Q1, Q3) | 41.00 (31.00, 49.00) | 38.00 (30.00, 42.50) | 43.00 (32.25, 53.50) | 0.150 |
| BMI, M (Q1, Q3) | 22.66 (20.00, 24.88) | 22.70 (20.59, 25.07) | 22.54 (19.78, 24.19) | 0.498 |
| Albumin(g/L), Mean ± SD | 36.63 ± 5.03 | 37.70 ± 4.98 | 34.50 ± 4.52 | 0.022* |
| Cholesterol (mmol/L), M (Q1, Q3) | 4.00 (3.30, 4.70) | 4.80 (4.35, 5.65) | 3.60 (3.10, 4.07) | < .001* |
| White Blood Cells (× 103/μL), M (Q1, Q3) | 6.63 (4.86, 8.43) | 6.39 (5.27, 8.11) | 6.71 (4.80, 8.56) | 0.847 |
| Erythrocyte Sedimentation Rate(mm/h), M (Q1, Q3) | 15.46 (2.30, 35.93) | 3.65 (1.53, 13.08) | 45.94 (29.38, 50.62) | < .001* |
| CRP(mg/L), M (Q1, Q3) | 4.04 (1.77, 9.69) | 2.29 (1.27, 3.98) | 13.31 (9.31, 15.59) | < .001* |
| Fecal Calprotectin(µg/g), M (Q1, Q3) | 133.17 (72.71, 213.58) | 84.12 (54.32, 139.06) | 255.36 (181.57, 367.54) | < .001* |
SD: standard deviation, M: Median, Q1: 1st Quartile, Q3: 3st Quartile